Dec 2 (Reuters) - Fennec Pharmaceuticals Inc FENC.O:
FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK® IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS
FENNEC PHARMACEUTICALS INC - STUDY SHOWS SIGNIFICANT REDUCTION IN HEARING LOSS IN 3-18 YEAR OLDS
FENNEC PHARMACEUTICALS INC - PEDMARK SHOWED NO INTERFERENCE WITH CISPLATIN ANTITUMOR ACTIVITY
FENNEC PHARMACEUTICALS INC - PLANS TO PURSUE REGISTRATION FOR PEDMARK IN JAPAN
Source text: ID:nGNX436j26
Further company coverage: FENC.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.